Shionogi Company Limited

Shionogi Seiyaku Kabushiki Kaisha

Murata Machinery, Ltd.

Takeshi Shiota

Nobuhiro Haga

Susumu Kamata

Saichi Matsumoto

Masami Takayama

Hiroshi Takemoto

Hirokuni Jyoyama

Toshihiko Okada

Hiroshi Tsuji

Shuji Yamada

Pharmaceutical compositions containing as an active ingredient compounds of the general formula (I), prodrugs of the same, pharmaceutically acceptable salts of both, or solvates of them and exhibiting thrombopoietin receptor agonism:X&#x2014;Y-Z-W&#x2003;&#x2003;(I)wherein Xis optionally substituted aryl, optionally substituted heteroaryl or the like; Yis &#x2014;NRCO&#x2014;(CH)&#x2014; or the like (wherein Ris a hydrogen or the like); Zis optionally substituted phenylene or the like; and Wis a group represeted by the below formula: wherein R, R, R, and Rare each independently a hydrogen atom, optionally substituted lower alkyl or the like, a broken line ( - - - ) represents the presence or absence of bond.

Compounds exhibiting thrombopoietin receptor agonism

Pharmaceutical compositions containing as an active ingredient compounds of the general formula (I), prodrugs of the same, pharmaceutically acceptable salts of both, or solvates of them and exhibiting thrombopoietin receptor agonism:wherein Xis optionally substituted heteroaryl or the like; Yis &#x2014;NRCO&#x2014; (CH)&#x2014; or the like (wherein Ris a hydrogen or the like); Zis optionally substituted arylene or the like; and Ais a ring represented by general formula (II) or (III):

Thiazolidine compounds and pharmaceutical compositions exhibiting thrombopoietin receptor agonism

The present invention relates to novel 3-benzylidene-1-carbamoyl-2-pyrroridone analogues having advantage anti-inflammatory activities, which is represented by the formula: ##STR1## wherein R.sup.1 and R.sup.2 each is independently hydrogen, alkyl, alkoxy, or halogen; R.sup.3 is hydrogen or acyl; R.sup.4 is hydrogen, alkyl, hydroxy, alkoxy, cyano, or halogen; R.sup.5 and R.sup.6 each is independently hydrogen, alkyl, aryl, aralkyl, heterocyclic group, substituted or unsubstituted amino, or OR.sup.7 wherein R.sup.7 is hydrogen, alkyl, aryl, acyl, or aralkyl, or taken together with the adjacent nitrogen atom may form heterocyclic group which may contain N, O, and/or S, and X and Y each is independently O, S, substituted or unsubstituted imino, or substituted or unsubstituted methylene. In more detail, the present invention provides an anti-inflammatory agent which is useful for the treatment of chronic inflammation and has little side effect, e.g., stomach disease.

3-benzylidene-1-carbamoyl-2-pyrrolidone analogues

3-benzylidene-1-carbamoyl-2-pyrrolidone compounds useful as

Growing community of inventors

Kyoto, Japan

Takeshi Shiota